Tweet
Pediatr Infect Dis J. 2010 Aug 18. [Epub ahead of print]
CROSS-REACTIVE NEUTRALIZING ANTIBODY AGAINST PANDEMIC 2009 H1N1 INFLUENZA A VIRUS IN INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS.
Hong DK, Tremoulet AH, Burns JC, Lewis DB.
From the Divisions of *Infectious Diseases, and daggerImmunology and Allergy, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Stanford, CA; and double daggerDepartment of Pediatrics, Kawasaki Disease Research Center, University of California, San Diego and Rady Children's Hospital, San Diego, CA.
Abstract
Prepandemic intravenous immunoglobulin (IVIG) and sera from Kawasaki disease patients treated with this IVIG were analyzed for 2009 H1N1-specific microneutralization and hemagglutination inhibition antibodies. All 6 different IVIG preparations tested had significant levels of cross-reactive-specific antibody at a concentration of 2.0 g/dL of immunoglobulin. Sera from 18 of 19 Kawasaki disease patients had significant increases of cross-reactive-specific antibody after 2.0 g/kg of prepandemic IVIG. These results suggest a role for adjunctive IVIG therapy for severe and/or drug-resistant 2009 H1N1 virus and other highly antigenically drifted influenza strains, particularly in the immunocompromised.
PMID: 20724956 [PubMed - as supplied by publisher]
CROSS-REACTIVE NEUTRALIZING ANTIBODY AGAINST PANDEMIC 2009 H1N1 INFLUENZA A VIRUS IN INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS.
Hong DK, Tremoulet AH, Burns JC, Lewis DB.
From the Divisions of *Infectious Diseases, and daggerImmunology and Allergy, Department of Pediatrics, Stanford University School of Medicine and Lucile Packard Children's Hospital, Stanford, CA; and double daggerDepartment of Pediatrics, Kawasaki Disease Research Center, University of California, San Diego and Rady Children's Hospital, San Diego, CA.
Abstract
Prepandemic intravenous immunoglobulin (IVIG) and sera from Kawasaki disease patients treated with this IVIG were analyzed for 2009 H1N1-specific microneutralization and hemagglutination inhibition antibodies. All 6 different IVIG preparations tested had significant levels of cross-reactive-specific antibody at a concentration of 2.0 g/dL of immunoglobulin. Sera from 18 of 19 Kawasaki disease patients had significant increases of cross-reactive-specific antibody after 2.0 g/kg of prepandemic IVIG. These results suggest a role for adjunctive IVIG therapy for severe and/or drug-resistant 2009 H1N1 virus and other highly antigenically drifted influenza strains, particularly in the immunocompromised.
PMID: 20724956 [PubMed - as supplied by publisher]
